Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP Resistance Markers and Falciparum Malaria Transmission
NCT00299247Phase 3Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- Dec 2006
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sulfadoxine, pyrimethamine in Plasmodium falciparum malaria, sponsored by National Institute of Allergy and Infectious Diseases. Status: withdrawn.
02
Drugs
sulfadoxinepyrimethamine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT00299247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00299247.